Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE
- PMLiVE

The Heart of the Matter 3 – Is pharma doing enough to maximise real world evidence?

RWE is currently de rigueur across pharma, and understandably so; getting it right may determine how brands perform in an evolving healthcare environment

- PMLiVE

The Heart of the Matter 2 – How is social media impacting publication planning?

The rise in digital communications, turbo-charged of late by social media, has wrought huge changes in the way health information is consumed, discussed and shared.

- PMLiVE

Communiqué Awards 2014 Digital Publication

See which healthcare communications programmes made a real difference to health outcomes with the Communiqué Awards digital publication.

- PMLiVE

The Heart of the Matter 1 – Closing the Clinical Care Gap

The application of evidence-based medicine, the role of behavioural science and the power of real world evidence, in association with McCann Complete Medical

- PMLiVE

10 Ways to drive sales force effectiveness

How to empower your account teams to meet the challenges of a changing marketplace

- PMLiVE

Innovating Outsourcing

2014 promises to be another exciting year for pharma and Ashfield

- PMLiVE

2013 Pharmaceutical Market Excellence Awards

See the 2013 PMEA Winners and Finalists.

- PMLiVE

Inside: CROs (2013/2014)

Your guide to contract research trends

- PMLiVE

Strategic communications for orphan drugs

The fourth in our series of supplements on orphan drugs and rare diseases, this last issue for 2013 covers the place of strategic communications.

- PMLiVE

Orphan drugs and rare diseases – value demonstration

The third in a series of supplements to look at orphan drugs and rare disease, this issue covers the role of value demonstration.

- PMLiVE

The Adherence Construct

How to build patient support programmes that last the course, in association with RAPP

- PMLiVE

Early access and regulation

The second in a series of supplements to look at orphan drugs and rare disease, this issue covers early access and regulation.